Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque P...

by Luís Puig, Martin Dossenbach, Lovisa Berggren, Anders Ljungberg, Claus Zachariae
Published 2019-08-01

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

by Lluís Puig, Mark Lomaga, Kristin Hollister, Yves Dutronc, Lovisa Berggren, Peter C.M. van de Kerkhof
Published 2020-12-01

Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature

by Imane Benabbad, Myriam Rosilio, Maité Tauber, Emmanuel Paris, Anne Paulsen, Lovisa Berggren, Hiren Patel, Jean-Claude Carel
Published 2018-05-01

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomize...

by Gil Yosipovitch, Adam Reich, Martin Steinhoff, Anke Beselin, Toby Kent, Martin Dossenbach, Lovisa Berggren, Carsten Henneges, Thomas Luger
Published 2018-11-01

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)

by Norman Wasel, Diamant Thaçi, Lars E. French, Curdin Conrad, Yves Dutronc, Gaia Gallo, Lovisa Berggren, Jean-Philippe Lacour
Published 2020-05-01